MYL News and Press, Mylan N.V. From 01/31/20

Pfizer (NYSE: PFE) recently reported fourth-quarter earnings that missed expectations on the top and bottom line. As a result, a jumpy stock market knocked a few percentage points off the stock price. Despite missing consensus forecasts, Pfizer stock looks like a perfect fit for dividend po...

As fears of a global pandemic continue to grip stock markets and crude oil, not even the biotechnology sector ( IBB ) could escape the wrath with IBB declining more than 6% from year-to-date highs. Indeed, although a handful of biotech names such as VIR which are developing vaccines for the...

The premise of generic drugs was simple enough. Branded medicines protected by a patent tend to be overpriced, but the equivalent therapy made by other companies once a patent expires should lead to price-lowering competition. As it turns out, however, generic drugs have become overpriced as wel...

Pharmaceutical giant  Pfizer (NYSE: PFE) reported fourth-quarter results Tuesday that beat expectations for revenue, but missed on the bottom line. That miss, combined with weak profit guidance, helped propel shares lower. The stock was trading down by more than 5% as of 3 p....

Relmada Therapeutics (NASDAQ: RLMD ) initiated with Buy rating and $75 (73% upside) price target at Jefferies. More news on: Relmada Therapeutics, Inc., Biogen Inc., Denali Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Shareholders of drugmaker Mylan (NASDAQ: MYL) are off to a good start this year, with an 8.4% gain after last year's 27% loss. The market may be thinking of the company's planned combination with Pfizer 's Upjohn business, which focuses on off-patent branded drugs and generics. The dea...

So far, stock market tailwinds because of end of year bonuses, retirement plan contributions, and institutional re-positioning have offset data suggesting the market is overbought. However, a 3% to 5% correction is getting more likely as the rally broadens out (excluding energy), suggesting in...

Source : ClearBridge Investments Editor's Note : The summary bullets for this article were chosen by Read more ...

Pfizer (NYSE: PFE) will provide patients of Roman, a men's health subsidiary of the privately held digital health company Ro, with the only Pfizer-authorized generic version of Viagra, a blockbuster erectile dysfunction treatment. IMAGE SOURCE: GETTY IMAGES. Under the deal, Pfizer's U...

On some levels, Rigel Pharmaceuticals (NASDAQ: RIGL) and Momenta Pharmaceuticals (NASDAQ: MNTA) are complete opposites. Rigel, based in South San Francisco, focuses on small molecule drugs while Momenta, headquartered in Cambridge, Massachusetts, tackles disease using large molecules cal...